{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:13:30Z","timestamp":1791112410395,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T00:00:00Z","timestamp":1092009600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> In the context of HIV infection and antiretroviral therapy, adiponectin concentrations have been shown to be related to lipodystrophy, metabolic alterations and HIV\u2010protease inhibitor (PI) use. The replacement of PI by nevirapine has improved the lipid profile of patients under antiretroviral therapy. The aim of the present study was to examine whether adiponectin concentration or insulin sensitivity level correlate with the modifications of lipid parameters after the switch of PI by nevirapine.<\/jats:p><jats:p><jats:bold>Material and methods\u2002<\/jats:bold> The evolution of metabolic parameters before and after 6\u00a0months of substitution of nevirapine for protease inhibitors was evaluated in a cohort of 55 HIV\u20101 infected patients. Adiponectin concentration, insulin sensitivity, lipid profile, cholesterol ester transfer protein (CETP) mass concentration and triglyceride enrichment of HDL were determined before and after the replacement of PI by nevirapine. Insulin sensitivity was evaluated by the HOMA model assessment.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Twenty\u2010four weeks of treatment with nevirapine improved significantly the lipid profile with a significant reduction of apoB (from 0\u00b798 to 0\u00b792\u00a0g\u00a0L<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7005) and triglyceride (from 2\u00b702 to 1\u00b766\u00a0mmol\u00a0L<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b702). HDL cholesterol and apoA1 increased significantly (from 0\u00b799 to 1\u00b719\u00a0mmol\u00a0L<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7001 and from 1\u00b740 to 1\u00b757\u00a0g\u00a0L<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001, respectively). The triglyceride enrichment of HDL significantly decreased after the replacement of PI by nevirapine (from 0\u00b7248\u00a0\u00b1\u00a00\u00b7092 to 0\u00b7213\u00a0\u00b1\u00a00\u00b7093; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7003). At baseline, and after 24\u00a0weeks of nevirapine treatment, we observed significant correlations between adiponectin level and lipid parameters [(HDL\u2010cholesterol (<jats:italic>r\u00a0=<\/jats:italic>\u00a00\u00b766, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7001 and <jats:italic>r\u00a0=<\/jats:italic>\u00a00\u00b769, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7001); triglycerides (<jats:italic>r\u00a0=<\/jats:italic>\u00a0\u22120\u00b742, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7002 and <jats:italic>r<\/jats:italic>\u00a0\u00a0=\u22120\u00b757, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7001), and triglyceride enrichment of HDL (<jats:italic>r\u00a0=<\/jats:italic>\u00a0\u22120\u00b743, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7005 and <jats:italic>r\u00a0=<\/jats:italic>\u00a0\u22120\u00b753, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7005)]. Twenty\u2010four weeks of treatment with nevirapine did not significantly change adiponectin concentrations (from 984 to 1086 \u00b5g\u00a0L<jats:sup>\u22121<\/jats:sup>, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b722), CETP mass and insulin sensitivity.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> This study shows that even though a strong correlation was found between adiponectin and some metabolic parameters at baseline and after 24\u00a0weeks of treatment by nevirapine, the improvement of lipid profile observed after the replacement of PI by nevirapine was not in relation to the change of plasma adiponectin concentration. The significant decrease of triglyceride enrichment of HDL after the replacement of PI by nevirapine probably leads to a decreased catabolism of HDL lipoprotein, and consequently explains the increase of plasma HDL concentration observed in this study.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2004.01379.x","type":"journal-article","created":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T16:17:13Z","timestamp":1092068233000},"page":"569-575","source":"Crossref","is-referenced-by-count":19,"title":["Serum adiponectin and metabolic parameters in HIV\u20101\u2010infected patients after substitution of nevirapine for protease inhibitors"],"prefix":"10.1111","volume":"34","author":[{"given":"J. M.","family":"Petit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Duvillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Bour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Brindisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Galland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guiguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Portier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63513-1"},{"key":"e_1_2_6_4_2","first-page":"547","article-title":"Protease inhibitors, diabetes mellitus and blood lipids","volume":"24","author":"Meyer L","year":"1998","journal-title":"Diabetes Metab"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199815000-00001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-199902000-00003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978655"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.7.700"},{"key":"e_1_2_6_9_2","first-page":"21","article-title":"Body habitus changes and metabolic alterations in protease inhibitor\u2010naive HIV 1\u2010infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli M","year":"2002","journal-title":"JAIDS"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199814000-00004"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200107010-00005"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200002180-00001"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/317541"},{"key":"e_1_2_6_14_2","first-page":"35","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan K","year":"2000","journal-title":"JAIDS"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000099786.99623.EF"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307040-00011"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021922"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1140"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021830"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207050-00010"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00008"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02367.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7827(02)00046-2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1201-1327"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300041-JLR200"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5286"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0022-2275(20)38740-X","article-title":"Role of triglyceride\u2010rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins","volume":"27","author":"Hopkins GJ","year":"1986","journal-title":"J Lipid Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(03)00078-X"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.14.7.1129"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2004.01379.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2004.01379.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:38:36Z","timestamp":1697240316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2004.01379.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1365-2362.2004.01379.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01379.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}